HRS5580

Unknown / undisclosed

Automated registry profile: compiled from public clinical-trial and regulatory records; not yet individually analyst-verified.

Ungradedevidence

Evidence outlook

Mid- and late-stage studies completed

This drug has completed mid- or late-stage studies. Where a sponsor has not posted registry results, topline data typically arrives via company announcements; see News.

How the evidence outlook works ↗

All registered studies

Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.

Phase 2 (2)
Postoperative Nausea and Vomiting
NCT07709897 · Fujian Shengdi Pharmaceutical Co., Ltd.
2026-08-06 – 2026-12 · Prevention of Postoperative Nausea and Vomiting
What this study did
NCT06475846 · Fujian Shengdi Pharmaceutical Co., Ltd.
2024-06-25 – 2024-10-29 · Preventing of Postoperative Nausea and Vomiting in Adults
What this study did

Competitive landscape

No competitors sharing a mechanism or indication in the current universe.

Upcoming events

(1 total)

Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Follow HRS5580 to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.

Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2026 (1)
December 2026 (1)
Phase 2Postoperative Nausea and VomitingRecruiting
Est. primary completion 2026-12 · NCT07709897 · CT.gov ↗
What to watch

See the full readout calendar ↗